BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/6/2020 8:11:47 AM | Browse: 910 | Download: 1450
 |
Received |
|
2019-11-27 13:48 |
|
Peer-Review Started |
|
2019-11-27 13:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-01-15 18:00 |
|
Revised |
|
2020-02-25 15:10 |
|
Second Decision |
|
2020-03-12 14:34 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-03-12 23:09 |
|
Articles in Press |
|
2020-03-12 23:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-04-01 03:47 |
|
Publish the Manuscript Online |
|
2020-04-06 08:11 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Glargine-300: An updated literature review on randomized controlled trials and real-world studies
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sujoy Ghosh and Romik Ghosh |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sujoy Ghosh, MD, Doctor, Doctor, Department of Endocrinology, IPGME&R, 244, Acharya Jagadish Chandra Bose Road, Bhowanipore, Kolkata 700020, West Bengal, India. drsujoyghosh2000@gmail.com |
| Key Words |
Insulin; Glargine-300; Type 2 diabetes; Diabetes mellitus; Hypoglycaemia; Glycaemic control |
| Core Tip |
Despite being a crucial therapeutic option in patients with diabetes, there is a clinical inertia for use of insulin due to fear of hypoglycaemia, weight gain, and complexity of insulin regimens or dosing. Insulin intensification is perceived to be associated with disease worsening, impeding optimal insulin titration and adequate glycaemic control. Insulin glargine 300, the second-generation long-acting insulin analogue, provides an extended and stable action profile, sustained glucose lowering, reduced risk of hypoglycaemia, less weight gain, and flexibility of dosing schedule. This review illustrates the clinical efficiency and safety demonstrated by insulin glargine 300 in randomised clinical trials and real-world studies. |
| Publish Date |
2020-04-06 08:11 |
| Citation |
Ghosh S, Ghosh R. Glargine-300: An updated literature review on randomized controlled trials and real-world studies. World J Diabetes 2020; 11(4): 100-114 |
| URL |
https://www.wjgnet.com/1948-9358/full/v11/i4/100.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v11.i4.100 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
